首页> 美国卫生研究院文献>Antimicrobial Agents and Chemotherapy >Bacteriocinogenic Clo DF13 Minicells of Escherichia coli Synthesize a Protein That Accounts for Immunity to Bacteriocin Clo DF13: Action of the Immunity Protein In Vivo and In Vitro
【2h】

Bacteriocinogenic Clo DF13 Minicells of Escherichia coli Synthesize a Protein That Accounts for Immunity to Bacteriocin Clo DF13: Action of the Immunity Protein In Vivo and In Vitro

机译:大肠杆菌的致细菌致病性Clo DF13小细胞合成一种蛋白质该蛋白质对细菌性细菌性Clo DF13具有免疫力:免疫蛋白在体内和体外的作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The Clo DF13 plasmid-specific immunity protein is able to prevent the inhibitory effect of cloacin DF13 on in vitro protein synthesis. We have shown, by gel filtration, that direct binding of the Clo DF13 immunity protein to cloacin occurs in vitro. This cloacin DF13-immunity protein complex is rather stable, and the cloacin present in the complex is no longer able to cause inhibition of in vitro protein synthesis. The binding of immunity protein to cloacin DF13 is rather specific because the Clo DF13 immunity protein does not bind to in vitro inactive cloacin and binds very poorly to the closely related bacteriocin colicin E3. Furthermore, we present data which strongly suggest that in vitro at least a fourfold excess of immunity protein is required to ensure that every cloacin molecule is inactivated by cloacin-immunity protein complex formation. Only a fraction (an about equimolar amount) of the immunity protein molecules, however, actually binds to cloacin DF13. The existence of an immunity protein-cloacin complex in vivo was concluded from the observation that cloacin, purified by chromatography on diethyl-(2-hydroxypropyl)-aminoethyl Sephadex in the absence of urea, contains an about equimolar amount of a second protein which comigrates with immunity protein on sodium dodecyl sulfate-polyacrylamide and urea-polyacrylamide gels. In an in vitro protein-synthesizing system, this component appeared to behave identical to the Clo DF13 immunity protein. The purified immunity protein-containing cloacin was at least 80 times less active in inhibiting in vitro protein synthesis, compared to cloacin, free of immunity protein. These data imply that few, if any, cloacin DF13 molecules are present in cloacinogenic cells as active, free cloacin molecules.
机译:Clo DF13质粒特异的免疫蛋白能够防止Cloacin DF13对体外蛋白合成的抑制作用。通过凝胶过滤,我们已经表明Clo DF13免疫蛋白与cloacin的直接结合发生在体外。该cloacin DF13-免疫蛋白复合物相当稳定,复合物中存在的cloacin不再能够抑制体外蛋白质合成。免疫蛋白与cloacin DF13的结合是相当特异性的,因为Clo DF13免疫蛋白不与体外失活的cloacin结合,并且与紧密相关的细菌素大肠杆菌E3的结合非常弱。此外,我们提供的数据强烈表明,在体外至少需要四倍过量的免疫蛋白,才能确保每个cloacin分子都能通过cloacin-免疫蛋白复合物的形成而失活。然而,实际上只有一小部分(大约等摩尔量)的免疫蛋白分子与泄殖腔DF13结合。通过观察发现,在不存在尿素的情况下在二乙基-(2-羟丙基)-氨基乙基葡聚糖凝胶上色谱纯化的cloacin包含约等摩尔量的第二蛋白,该免疫蛋白-cloacin复合物在体内的存在可以得出结论。在十二烷基硫酸钠-聚丙烯酰胺和尿素-聚丙烯酰胺凝胶上具有免疫蛋白。在体外蛋白质合成系统中,该成分的行为似乎与Clo DF13免疫蛋白质相同。与不含免疫蛋白的cloacin相比,纯化的含免疫蛋白的cloacin抑制体外蛋白质合成的活性至少低80倍。这些数据表明,在凝乳素生成细胞中几乎没有作为活性,游离凝乳素分子存在的凝乳素DF13分子。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号